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Differentiation of Adrenal Adenoma and
Nonadenoma in Unenhanced CT: New
Optimal Threshold Value and the Usefulness
of Size Criteria for Differentiation
Objective: To determine the optimal threshold for the attenuation values in
unenhanced computed tomography (CT) and assess the value of the size criteria
for differentiating between an adrenal adenoma and a nonadenoma. 
Materials and Methods: The unenhanced CT images of 45 patients at our
institution, who underwent a surgical resection of an adrenal masses between
January 2001 and July 2005, were retrospectively reviewed. Forty-five adrenal
masses included 25 cortical adenomas, 12 pheochromocytomas, three lym-
phomas, and five metastases confirmed by pathology were examined. The CT
images were obtained at a slice thickness of 2 mm to 3 mm. The mAs were var-
ied from 100 to 160 and 200 to 280, while the 120 KVp was maintained in all
cases. The mean attenuation values of an adrenal adenoma and nonadenoma
were compared using an unpaired t test. The sensitivity, specificity, positive pre-
dictive value, negative predictive value, and accuracy at thresholds of 10 HU, 20
HU, and 25 HU were compared. The diagnostic accuracy according to the size
criteria from 2 cm to 6 cm was also compared.
Results: The twenty-five adenomas showed significantly lower (p < 0.05)
attenuation values (mean SD; 16.3 14.9) than the nonadenomas (38.1 6.8).
Nineteen (90%) of the 20 nonadenomas had attenuation values ranging from 30
to 50 HU. The sensitivity, specificity, positive predictive value, negative predictive
value, and accuracy for diagnosing adenomas were 36%, 100%, 100%, 56%,
and 64%, respectively, at a threshold of 10 HU; 60%, 100%, 100%, 67%, and
78%, respectively, at a threshold of 20 HU; and 72%, 95%, 95%, 73%, and 82%,
respectively, at a threshold of 25 HU. The adenomas had a significantly (p < 0.05)
smaller diameter (2.44 1.24 cm) than the nonadenomas (5.09 2.37 cm). The
size criteria using a diameter of 4 6 cm showed a sensitivity > 90% but a speci-
ficity < 70%. Size criteria of 2 or 3 cm had a high specificity of 100% and 80% but
a low sensitivity of 20% and 60%. 
Conclusion: The threshold attenuation values of 20 or 25 HU in the unen-
hanced CT appear optimal for discriminating an adrenal adenoma from a non-
adenoma. The size criteria are of little value in differentiating adrenal masses
because of their low specificity or low sensitivity.
drenal masses are found in approximately 5 10% of patients in imaging
procedures performed for reasons unrelated to the adrenal glands (1 3).
The reported prevalence of adrenal adenomas in an autopsy series is
even more variable (1 32%) (4, 5). Most incidentalomas are benign and nonhyper-
secretory in patients without a known extraadrenal malignancy (3, 6). Some studies
have shown that the majority of adrenal masses are benign adenomas, which consti-
tute a significant fraction even in patients with a known extraadrenal primary
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malignancy (7).
Therefore, distinguishing adenomas from non-adenoma-
tous adrenal masses, particularly metastatic ones, is of
great importance in cancer patients. The application of a
percutaneous biopsy, which is the gold standard for charac-
terizing adrenal masses, is a suboptimal choice, as it is an
invasive procedure with well-documented risks of compli-
cations. Furthermore, its accuracy is only 80 90%, due to
sampling errors or inadequate specimen sizes in practice
(8), and it is least helpful in distinguishing between benign
adrenal adenomas and primary adrenocortical carcinomas
(9, 10). Noninvasive characterization of masses such as
adenomas, is generally preferred (11) because they have
the potential to reduce the number of percutaneous
biopsies if the results are sufficiently specific (12). 
Although most small adrenal masses represent benign
cortical adenomas, the morphological features alone
cannot reliably differentiate between an adenoma and a
primary or metastatic lesion (11, 13). Many studies have
suggested that the attenuation value in unenhanced CT,
which is expressed in Hounsfield Units (HU), can be used
to distinguish between an adenoma and other abnormali-
ties (14 17). The utility of unenhanced CT is based on
intracytoplasmic fat, which is often more abundant in
adrenal adenomas but rare in adrenal metastases,
pheochromocytomas, or adrenocortical carcinomas (18).
The threshold values for noncontrast CT in HU units,
ranging from 0 HU to 20 HU, have been suggested in the
literature, and a value of 10 HU was recommended by a
consensus panel organized by the National Institutes of
Health (1, 19 24). In practice, we frequently encountered
adrenal adenomas with attenuation values > 10 HU.
Therefore, many adrenal adenomas will be excluded when
applying a threshold of 10 HU on an absolute scale, which
would lead to a relatively low sensitivity in differentiating
adenomas from nonadenomas and more false negative
results. We hypothesized that an attenuation value > 10
HU can be used to differentiate an adenoma from nonade-
nomas on unenhanced CT. The aim of this study was to
determine the optimal threshold of the attenuation values
in unenhanced CT for making a distinction between
adrenal adenomas and nonadenomas.
MATERIALS AND METHODS
Patients and Proof of Lesions
One hundred fifteen adrenalectomies were performed at
our institution from January 2001 through to July, 2005.
The abdominal CT results of all of these cases were
reviewed. Seventy cases were excluded from the study for
the following reasons: the CT results were unreadable, lost
or CT scans were performed with intravenous contrast
enhancement but without an unenhanced scan. The other
reasons for patient exclusion included a mass sizes < 1 cm
in nine patients, the presence of artifacts on the images that
prevented the region of interest (ROI) from being
measured, and five cases of masses with grossly visible fatty
components < 30 HU, which were presumed to be
myelolipomas. This left a total 45 cases of adrenal masses,
with CT scans containing the available precontrast images,
which were reviewed retrospectively. For the five cases
with bilateral adrenal masses, the larger of the two masses
was selected. There were 17 men and 28 women with a
mean age of 46.4 2.2 years (range, 15 72 years). The
final diagnosis of these adrenal masses was made by a
histopathology examination of the adrenalectomy
specimens. The adrenal masses consisted of 25 cortical
adenomas and 20 nonadenomas, which in turn consisted of
12 pheochromocytomas, three lymphomas, and five
adrenal metastases. The primary malignancies in the cases
where the adrenal metastasis was a later development were
renal cancers in two patients and one each with ovarian
cancer, hepatocellular carcinoma, and breast cancer.
CT Techniques
A Somatom Sensation 16 MDCT scanner (Siemens,
Forchheim, Germany) was used in 24 patients, with the
following settings: 16 0.75 mm collimation and 0.5 sec
rotation speed, 120 kV, 100 160 mAs, and a 12
mm/rotation table-feed. The final images were
reconstructed with a 2 mm increment and a 2 mm
thickness. A Light Speed Plus 4 multidetector-row CT
(MDCT) scanner (GE Medical Systems, Milwaukee, WI)
was used for 13 patients, with the following settings: 120
kV, 240 280 mAs, a table speed of 7.5 mm per rotation,
high-quality mode, and a pitch of 3:1. The final scans were
reconstructed at 3-mm intervals, with a 2 3 mm slice
thickness. A High Speed single-section spiral CT (GE
Medical Systems, Milwaukee, WI) was used for the
remaining eight patients, with the following settings:
120kV and mA from 200 to 280. The final scans were
reconstructed at 3-mm intervals, with a 2 3 mm slice
thickness. Twenty-three of the 45 cases followed the
adrenal protocol with relatively thin reconstruction
intervals and thin slices in each CT machines, while the
remaining 22 cases followed the abdomen protocol,
abdomen-pelvis protocol, or liver dynamic protocol.
Analysis of CT Scans
The images were reviewed retrospectively by a single
radiologist on a PACS (picture archiving and communica-
tion system) workstation (Centricity workstation, version
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2.0; GE Medical System). The attenuation of the lesions
was measured, using an circular or ovoid ROI set as large
as possible but entirely contained within the boundary of
the adrenal lesion in order to avoid partial volume averag-
ing with the surrounding tissue. The mass boundary was
avoided and areas of necrosis or cystic changes were
excluded from the ROI measurement. The range of ROI
measurements for adrenal lesions in the CT scans were
relatively wide, from 10 mm2 to 776 mm2. The ROI range
for adenomas was from 10 mm2 to 597 mm2 and from 20
mm2 to 776 mm2 for nonadenomas. The analysis of CT
images was confined to the attenuation value on the
unenhanced CT images for the purposes of this study. The
other imaging characteristics, such as the attenuation value
on the contrast enhancement images, shape, morphology
of lesions, weight, or the biochemical state of the patients
were not examined. A primary investigator measured the
maximum diameter of the masses in the transverse images.
Statistical Analysis of Attenuation Values
The mean unenhanced attenuation value of the adrenal
adenomas and nonadenomas were calculated for each
group and analyzed using an unpaired Student’s t test,
using SPSS software (SPSS for windows, 12.0.0 standard
version, LEAD Technologies, Inc.). A p-value < 0.05 was
considered significant.
The sensitivity, specificity, positive predictive value,
negative predictive value and accuracy for any specific
threshold were calculated and compared at 10 HU, 20 HU,
and 25 HU. In this study, the sensitivity was defined as the
probability that an adrenal mass would be classified as an
adenoma, given that it was truly an adenoma. The
specificity was defined as the probability that an adrenal
mass would be classified as a nonadenoma, given that it is
was truly a nonadenoma. The sensitivity, specificity,
positive predictive value (PPV), negative predictive value
(NPV), and accuracy, which were calculated at the cutoff
threshold diameters of 2 6 cm, were compared.
Receiver Operating Characteristic Analysis
The receiver operating characteristic (ROC) curves for
the attenuation values at the unenhanced CT and for the
mass sizes were generated from the data using SPSS
software (SPSS for windows, 12.0.0 standard version,
LEAD Technologies, Inc.). For each discriminator, the
ROC curve is a plot of the true-positive fraction (TPF =
sensitivity) against the false-positive fraction (FPF = 1-
specificity). The SPSS program fits the ROC curves to the
data, estimates the area under curve as a measure of its
effectiveness of a discriminator, and provides the likeli-
hood that the observed differences could have arisen by
chance.
RESULTS
The attenuation values on the unenhanced CT ranged
from 13.6 to 38.7 HU (mean SD; 16.3 1.5) for
adenomas and 20.6 to 49.1 HU (38.1 6.8) for nonade-
nomas. The difference was statistically significant (p =
0.001).
Figure 1 shows a scattergram of the attenuation values
on the unenhanced CT of 25 adenomas and each group of
20 nonadenomas. The attenuation values were negative in
four (16%) adenomas, > 10 HU in 16 (64%) adenomas,
and > 30 HU in seven (28%) adenomas. These seven
attenuation values > 30 HU overlapped with the range of
nonadenomas. All masses with attenuation < 20 HU were
adenomas. Among the 20 nonadenomas, none had an
attenuation value < 20. Eighteen (90%) nonadenomas had
attenuation values > 30 HU. The attenuation values for the
pheochromocytomas ranged from 36.6 HU to 49.1 HU,
with a mean value of 40.0 5.7 HU. All the metastases
had values > 30 HU ranging from 33.4 HU to 36.6 HU
with a mean value of 35.3 1.3 HU. The attenuation
values of the three lymphomas were the lowest among the
nonadenoma groups, ranging from 20.6 HU to 32.7 HU
with a mean value of 25.6 6.1 HU. Table 1 shows the
sensitivity, specificity, positive predictive value, negative
predictive value, and accuracy calculated for each thresh-
old value. At a threshold value of 10 HU, the sensitivity
(36%) and NPV (56%) values were lowest, even though
the specificity and PPV were 100%. At a threshold value
of 20 HU, the sensitivity and NPV were increased to 60%,
while the specificity and positive predictive value were
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Table 1. Sensitivity, Specificity, PPV, NPV and Accuracy at 10 HU, 20 HU and 25 HU
Threshold Sensitivity Specificity PPV* NPV Accuracy
10 HU 9/25 (36%) 20/20 (100%) 9/9 (100%) 30/36 (56%) 29/45 (64%)
20 HU 15/25 (60%) 20/20 (100%) 15/15 (100%) 20/30 (67%) 35/45 (78%)
30 HU 18/25 (72%) 19/20 (95%) 18/19 (95%) 19/26 (73%) 37/45 (82%)
Note. Data in parentheses are percentages.
* PPV = positive predictive value,    = negative predictive value
maintained at 100%. At a threshold value of 25 HU, the
sensitivity was further increased to 72%, but the specificity
(95%) and positive predictive value (95%) decreased.
The mean diameter of the adrenal adenomas was 2.4
1.2 cm ranging from 1.0 cm to 6.3 cm. The mean diameter
of the nonadenomas was 5.1 2.4 cm, ranging from 1.0 cm
to 9.8 cm. Figure 2 shows a scattergram of the adenomas
and nonadenomas according to their size. There were
statistically significant differences between the diameter of
the adenomas and nonadenomas (p = 0.015). One adrenal
metastasis measured 1 cm in the largest diameter, and
there were three malignant adrenal masses < 3 cm in the
largest diameter. Fourteen (70%) nonadenomas measured
< 6 cm in the largest diameter, and all were malignant.
Table 2 shows the sensitivity, specificity, PPV, NPV, and
accuracy at each tumor diameter. In ROC analysis, the
area under the ROC curve for CT attenuation values
(0.904 0.044) was larger than that for size (0.860
0.060) (Fig. 3), which indicates the unenhanced attenuation
value is more useful in distinguishing between adenomas
and nonadenomas than the mass size (Figs. 4 6).
DISCUSSION
The high lipid content of most adrenal cortical adenomas
produces the low attenuation values on the CT images
(25). Significant differences in the mean lipid content have
been documented between benign adrenal adenomas and
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Table 2. Sensitivity, Specificity, PPV, NPV, and Accuracy According to the Tumor Diameter
Size Criteria Sensitivity Specificity PPV* NPV Accuracy
2 cm 5/25 (20%) 20/20 (100%) 5/5 (100%) 20/40 (50%) 25/45 (56%)
3 cm 15/25 (60%) 16/20 (80%) 15/19 (79%) 16/26 (62%) 31/45 (69%)
4 cm 23/25 (92%) 14/20 (70%) 23/29 (79%) 14/16 (88%) 37/45 (82%)
5 cm 23/25 (92%) 9/20 (45%) 23/34 (68%) 9/11 (82%) 32/45 (71%)
6 cm 24/25 (96%) 5/20 (25%) 24/39 (62%) 5/6 (83%) 29/45 (64%)
Note. Data in parentheses are percentages.
* PPV = positive predictive value,    = negative predictive value
Fig. 2. Scattergram of the adenomas and nonadenomas accord-
ing to their size.
Fig. 1. Scattergram of the attenuation values in the unenhanced
CT of 25 adenomas and each group of 20 nonadenomas (NA-L:
lymphoma, NA-M: metastasis, NA-P: pheochromocytoma). Note
that all masses with a HU < 20 were adenomas. Among the 20
nonadenomas, none had an attenuation value < 20, and eighteen
(90%) of the nonadenomas had attenuation values > 30 HU.
adrenal carcinomas both in vitro and in vivo (26). The
mean lipid content in adrenal adenomas was 13.4%,
compared with 3.5% in adrenal carcinomas, which is a
distinctive feature that can be used to differentiate
adenomas from other adrenal masses (27). Some
researchers have reported negative mean attenuation
values for adrenal adenomas, with a significant difference
in mean attenuation values between adenomas and
nonadenomas. A few reports found positive mean attenua-
tion values for adrenal adenomas in nonenhanced CT,
ranging from 2.2 to 13.0 HU (15, 17, 28). In the present
study, the 25 adrenal adenomas had a mean attenuation
value of 16.3 14.9, which is higher than those reported
elsewhere. The unenhanced CT has proven to be a useful
tool for making a radiological diagnosis of adrenal cortical
adenomas (18). Several studies have attempted to define a
specific threshold to distinguish between benign and
malignant lesions, and many studies suggested a cutoff
threshold of between 0 and 18 HU as the optimal value
(12, 15, 17, 21, 28). Using a lower threshold value tends to
Park et al.
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Fig. 3. Receiver operating characteristic curve for unenhanced CT attenuation value in enabling differentiation of adenomas from
nonadenomas (A) and receiver operating characteristic curve for the size of adrenal lesions (B). The area under the receiver operating
characteristic curve for CT attenuation values (0.904 0.044) was larger than that for size (0.860 0.060), indicating a greater ability of
unenhanced CT attenuation value for distinguishing adenomas from nonadenomas.
A B
Fig. 4. Example of a typical adrenal adenoma in the noncontrast
image. A 1.6 1.2 cm, well-defined, low attenuated nodule
(arrow) is shown in the left adrenal gland with a HU value of 
13.6. This nodule was confirmed to be an adrenal adenoma by
a pathological examination.
Fig. 5. Non-contrast CT image of a 57 year-old female adrenal
gland, showing a 2.9 2.7 cm, round-shaped nodule (arrow) in
the left adrenal gland with a HU value of 38.7. The nodule was
confirmed to be a benign adrenal adenoma by a pathological
examination.
produce a high specificity for lesion characterization but
poor sensitivity, which results in many adrenal lesions
requiring additional CT or MR imaging. On the other hand,
threshold values toward the high end of the spectrum tend
to produce high sensitivity but poor specificity for tissue
characterization. 
The specificity for making a diagnosis of adrenal
adenoma needs to be close to 100% in order to prevent
misdiagnoses of adrenal metastasis. However, the sensitiv-
ity is also important for practical reasons because of the
high incidence of adenoma, compared with that of a
nonadenoma. In order to prevent missing malignancies,
applying low threshold values with a high specificity and
low sensitivity will result in more indeterminate lesions,
which will necessitate further imaging or a percutaneous
biopsy. Boland et al. (21) proposed that higher threshold
values for identifying adrenal lesions may be a better
choice, depending on the relative incidence of benign and
malignant lesions, as well as the costs and benefits of
avoiding false negative or false positive diagnoses. In this
study, a threshold value of 20 HU provided a specificity,
sensitivity, PPV and accuracy of 100%, 60%, 100%, and
56%, respectively. At a threshold value of 25 HU, the
specificity decreased to 95%, but the sensitivity and
accuracy increased to 72% and 82%, respectively. Based
on these results, the optimal threshold CT attenuation
value for differentiating between an adrenal adenoma and
nonadenoma is 20 HU or higher, which is higher than the
values recommended in previous studies.
Recently many reports have suggested that the percent-
age change in the washout of the contrast material on the
dynamic and delayed contrast-enhanced CT can be a
highly specific method for differentiating adrenal
adenomas from nonadenomas (22, 29). These suggestions
are based on the observation that adrenal adenomas show
more rapid and greater washout of the contrast material
than adrenal nonadenomas. Therefore, the percentage
change in washout is a useful criterion for differentiating
adrenal adenomas from nonadenomas (29, 30). This
method is particularly important for lipid-poor adenomas
because there is significant overlap of the mean attenua-
tion values on unenhanced CT between the lipid-poor
adrenal adenomas and nonadenomas (30). Caoili et al. (30)
suggested that almost all adrenal masses can be correctly
categorized as adenomas or nonadenomas with a combina-
tion of unenhanced and delayed enhanced CT. In this
study, the adrenal adenomas were not classified into the
lipid-rich and lipid poor types, and there was some overlap
of the unenhanced attenuation values over 30 HU between
the adenomas and nonadenomas. Moreover, the
unenhanced CT attenuation value on its own does not
allow accurate differentiation in this overlapped groups. In
indeterminate adrenal lesions in unenhanced CT, particu-
larly in patients with a history of a malignancy, additional
work-up will be needed to diagnose and differentiate
adenomas from nonadenomas by calculating the washout
profile of contrast in the enhanced CT. Regardless of some
overlap in the range of attenuation values > 30 HU on the
unenhanced CT between two groups, which will require
additional work up, the results of this study suggest that
attenuation value 20 HU or 25 HU may be an acceptable
cut off value on unenhanced CT scan to differentiate
between adrenal adenomas and nonadenomas with a high
specificity and sensitivity. 
Many studies have suggested that the size of adrenal
tumors is an important determinant for differentiating
adrenal adenomas from nonadenomas (31 33). There is a
significant increase in the frequency of malignancy with
increasing adrenal tumor size (32, 33). Korobkin et al. (34),
in a study of 135 adrenal masses, reported that the mean
diameter of adenomas was significantly lower than that of
nonadenomas (2.4 versus 4.5 cm) but that there was a
sufficient overlap between the two groups, particularly
with the smaller lesions. These results showed very similar
results, with the mean maximal diameter of adenomas
being significantly smaller than that of nonadenomas.
Grouping the adrenal masses by their size at 4 cm, 5 cm,
and 6 cm in the largest diameter yielded a relatively high
sensitivity of more than 90% but a specificity of only 25%
70%. The group with masses 2 or 3 cm in the largest
diameter showed increased specificity but decreased
sensitivity. Therefore, these results support previous
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Fig. 6. Noncontrast abdominal CT scan of 17-year-old male,
showing a 5.4 3.3 cm right adrenal mass (arrow) with a HU
value of 33.4, which was suggestive of a nonadenoma rather
than an adrenal adenoma. This mass was confirmed by a
pathological examination to be a right adrenal metastasis from a
renal cell carcinoma. 
reports in that the size criteria are of little value when
discriminating between benign adrenal masses and adrenal
gland metastasis (6, 35).
This study had several limitations. First, there was a
relatively small number of cases, with a particularly small
number of metastases included in the nonadenomas group.
In a literature review, Hamrahian et al. (36) performed
their study, based on 157 adrenal adenomas/hyperplasia
and 142 nonadenomas, including 35 adrenal metastases.
Miyake et al. analyzed 14 nonfunctioning adrenal
adenomas and 22 nonadenomas, including 16 metastases
(19). Korobkin et al. examined 93 cortical adrenal
adenomas and 42 malignant adrenal lesions, including 34
metastases (12). However, not all of the cases included in
those studies have been verified pathologically. The second
limitation is that several CT machines were used, and the
scan parameters were not standardized and there was a
relatively wide range of mAs, from 100 160 and 200
280 mAs. However, the study population included a long
clinical follow-up and the results obtained from those
diverse CT systems may suggest the general applicability
of these results to future cases. Thirdly, there is a possibil-
ity of selection bias in the group of adrenal adenomas.
Adrenal lesions with 10 HU or less on the unenhanced CT
usually undergo a CT follow up rather than an adrenalec-
tomy or do not undergo additional follow up. In this study,
all data regarding adenomas were based on pathologically
confirmed ones by an adrenalectomy only. Adenomas
diagnosed with an additional CT scan without a pathologi-
cal diagnosis were excluded. 
In conclusion, 20 or 25 HU is proposed as the optimal
threshold attenuation value on the nonenhanced CT for
discriminating between adrenal adenomas and nonadeno-
mas. These results show that the attenuation values on the
unenhanced CT are superior to the size criteria in differen-
tiating adrenal adenomas from an adrenal malignancy, and
grouping by the tumor size is of little value due to the low
specificity and sensitivity. 
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